Abstract
The aim of the study was to analyze the real-world treatment patterns of adjuvant chemotherapy administration among patients with resected pancreatic adenocarcinoma. Cases with non-metastatic pancreatic adenocarcinoma, diagnosed 2007–2018, treated with upfront surgical resection, and recorded within Alberta Cancer registry were accessed. Multivariable logistic regression analysis was conducted to evaluate factors predicting use of adjuvant chemotherapy. Kaplan–Meier survival estimates and multivariable Cox regression analysis were used to compare overall survival among patients treated with adjuvant gemcitabine versus those treated with adjuvant gemcitabine + capecitabine. A total of 695 patients who have undergone upfront surgical treatment of pancreatic adenocarcinoma, including 445 patients (64%) who received adjuvant chemotherapy and 250 patients (36%) who did not receive adjuvant chemotherapy. The following factors were associated with lower probability to receive adjuvant chemotherapy: older age (OR 0.94; 95% CI 0.93–0.96), node negativity (OR 0.47; 95% CI 0.33–0.67), higher Charlson comorbidity index (OR 0.86; 95% CI 0.74–0.99), and living within the Northern zone of the province (OR for Calgary zone versus North zone: 2.24; 95% CI 1.29–3.90). Within patients who received adjuvant gemcitabine ± capecitabine, factors associated with worse overall survival included higher Charlson comorbidity index (HR 1.18; 95% CI 1.00–1.40), and node-positive disease (HR for node-negative versus node-positive disease: 0.51; 95% CI 0.33–0.78). Type of chemotherapy was not predictive of overall survival (HR for gemcitabine versus gemcitabine plus capecitabine: 1.40; 95% CI 0.98–2.00). P value for interaction between type of chemotherapy and nodal status was 0.038. In this real-world study, the added benefit of adjuvant gemcitabine + capecitabine (compared to adjuvant gemcitabine) seems to be limited to patients with node-positive disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Winer LK, Cortez AR, Ahmad SA, Wima K, Olowokure O, Latif T, et al. Evaluating the impact of ESPAC-1 on shifting the paradigm of pancreatic cancer treatment. J Surg Res. 2020. https://doi.org/10.1016/j.jss.2020.09.009.
Watson MD, Miller-Ocuin JL, Driedger MR, Beckman MJ, McKillop IH, Baker EH, et al. Factors associated with treatment and survival of early stage pancreatic cancer in the era of modern chemotherapy: an analysis of the national cancer database. J Pancreat Cancer. 2020;6(1):85–95.
Daamen LA, Groot VP, Besselink MG, Bosscha K, Busch OR, Cirkel GA, et al. Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: A nationwide analysis. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004093.
Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/Nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020. https://doi.org/10.1097/SLA.0000000000004155.
Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, et al. Role of surgery and perioperative therapy in older patients with resectable pancreatic ductal adenocarcinoma. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0086.
Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.
Ma SJ, Iovoli AJ, Hermann GM, Prezzano KM, Singh AK. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer. Cancer Med. 2019;8(9):4110–23.
Ma SJ, Oladeru OT, Miccio JA, Iovoli AJ, Hermann GM, Singh AK. Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer. JAMA Netw Open. 2019;2(8):e199126.
https://www.albertahealthservices.ca/assets/about/publications/ahs-ar-2017/zones.html. Accessed 29 Nov 2020.
https://www.albertahealthservices.ca/assets/about/publications/ahs-ar-2020/zones.html. Accessed 29 Nov 2020.
Iott MJ, Corsini MM, Miller RC. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas. Clin J Oncol Nurs. 2008;12(4):599–605.
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.
Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, et al. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Cancer. 2019;125(1):57–67.
Mungo B, Croce C, Oba A, Ahrendt S, Gleisner A, Friedman C, et al. Controversial role of adjuvant therapy in node-negative invasive intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08916-6.
Abdel-Rahman O, Koski S, Mulder K. Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. Int J Colorectal Dis. 2020. https://doi.org/10.1007/s00384-020-03778-6.
Banerjee R, Yi JC, Majhail NS, Jim HSL, Uberti J, Whalen V, et al. Driving distance and patient-reported outcomes in hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2020. https://doi.org/10.1016/j.bbmt.2020.08.002.
Acknowledgements
The authors would like to thank the analytical teams at Surveillance and reporting and CancerControl Alberta for their help in data extraction.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
12032_2021_1469_MOESM1_ESM.png
Supplementary file 1 (PNG 96 KB) Supplementary figure-1: Overall survival according to receipt of adjuvant chemotherapy; a) among patients with node negative disease; b) among patients with node positive disease.
12032_2021_1469_MOESM3_ESM.jpg
Supplementary file 3 (PNG 56 KB) Supplementary figure-2: Overall survival according to type of adjuvant chemotherapy; a) among patients with node negative disease; b) among patients with node positive disease.
Rights and permissions
About this article
Cite this article
Abdel-Rahman, O., Spratlin, J. & Koski, S. Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. Med Oncol 38, 18 (2021). https://doi.org/10.1007/s12032-021-01469-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-021-01469-y